A Phase 3, Double-blind, Randomized Study to Compare the Efficacy and Safety of Rituximab Plus Lenalidomide (CC-5013) Versus Rituximab Plus Placebo in Subjects With Relapsed/Refractory Indolent Lymphoma
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 16 Oct 2017
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab (Primary)
- Indications Follicular lymphoma; Marginal-zone-B-cell-lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms AUGMENT
- Sponsors Celgene Corporation
- 17 Apr 2017 Planned primary completion date changed from 31 Mar 2017 to 29 Dec 2017.
- 17 Apr 2017 Status changed from recruiting to active, no longer recruiting.
- 27 Feb 2017 Planned End Date changed from 1 Dec 2021 to 28 Dec 2021.